All News

close up of a stethoscope

Rheumatoid Arthritis ILD Complications

Scott Matson, MD

I'm a pulmonologist at the University of Kansas in Kansas City, and I'm excited to talk about one of my favorite topics: treatment complications in rheumatoid arthritis- associated interstitial lung disease or RA-ILD. One of the reasons I think this is a pressing and important topic is what we're dealing with here is a group of patients who have really poor outcomes, even with the significant advances that the rheumatology community's been able to make in the management of the underlying synovial disease.

Read Article
ILD damage fibrosis path

Abatacept and Methotrexate may Lower Risk of Interstitial Lung Disease in RA

Jack Cush, MD

A post hoc, pooled analysis of of rheumatoid arthritis (RA) clinical trials shows those received abatacept had a lower rate of Interstitial lung disease (ILD).

Read Article
lung%2Cbright.jpg

Multi-omics, biomarkers, rheumatoid arthritis and pulmonary fibrosis

Jack Cush, MD

Rheumatoid arthritis (RA) is a common autoimmune disease, and approximately 30%-40% of patients develop pulmonary complications such as idiopathic pulmonary fibrosis (IPF), but the causal relationship between the two has long been unclear.

Read Article
RheumNow Podcast square

ILD Begins (8.29.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from RheumNow.com. This week news on vaccines, safety of acetaminophen and more.

Read Article
heart.EKG_.CVD_.jpg

Cardiovascular Sequelae in Adults After Kawasaki Disease

Jack Cush, MD

A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD adults and later, a second surge in their late 30s. 

Read Article
takayasu.jpg

TNF Inhibitors in Takayasu's Arteritis

Jack Cush, MD

A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and  subcutaneous adalimumab in patients with Takayasu arteritis.

Read Article
Combined Therapy in Rheumatoid Arthritis Interstitial Lung Disease RA-ILD is a major therapeutic evidence gap in treatment, affecting 8% of patients. It was often under-diagnosed, leading to more severe cases and inflated mortality rates. Despite advancements, RA-ILD, https://t.co/Q8mMxtBgZZ
Dr. John Cush RheumNow ( View Tweet)
Retrospective Korean study of #RA & ILD pts (n 151) - ILD duration & UIP pattern significantly affected prognosis. 62% were non-smokers, DAS28=4.9, UIP in 60%. @4 years, ILD progressed in 58%; mortality=21%. MTX did not affect progression or mortality. https://t.co/1XNcWsAuea https://t.co/hsUWi27OtQ

Links:

Dr. John Cush RheumNow ( View Tweet)
Biomarkers in ILD Join Elena K. Joerns, MD, as she highlights key insights on the role of biomarkers in ILD. Sponsored By: Boehringer Ingelheim. https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/tQUvwHD5cX

Links:

Dr. John Cush RheumNow ( View Tweet)
September is Pulmonary Fibrosis Awareness month. PF & ILD affect more than 250,000 Americans. The Pulmonary Fibrosis Foundation (PFF), will lead a nationwide campaign to raise awareness https://t.co/BYKeLcFP2U https://t.co/746CyLCT0z

Links:

Dr. John Cush RheumNow ( View Tweet)
Interstitial lung disease is a group of conditions that cause inflammation and scarring in the lungs. This JAMA Patient Page describes types and causes of interstitial lung disease as well as its diagnosis, treatment, and prognosis. https://t.co/WELKKR0SX7 https://t.co/ykzR16ja3L

Links:

JAMA JAMA_current ( View Tweet)
Anti-MDA5 DM is assoc w/ rapidly progr ILD & mortality risk. 26 MD5+ DM pts (age 56.6 yrs; 7/26 male) Sxs: Gottrón’s (81%), ILD (73%), periungual erythema (69%), heliotrope (61%), V-sign (42%), arthritis (42%), weakness (38%), mechanic’s (35%), Raynaud’s (19%). 7/19 RP-ILD died https://t.co/ugbmKlXsBp
Dr. John Cush RheumNow ( View Tweet)
LIVE September 9th, 7PM EST Join Drs. Sindhu Johnson, Anna-Maria Hoffmann-Vold, Scott Matson & Jack Cush, Moderator, as they review ACR & EULAR #ILD guidelines. Where are we now? Where are we going? Don’t miss it! https://t.co/PVo0dbQLCn #Rheumatology #ILD https://t.co/gp1qfeEt3S

Links:

Dr. John Cush RheumNow ( View Tweet)
MUC5 mutations not in SSc-ILD. Study of 2363 SSc-ILD, 3526 SSc w/o ILD & 15076 controls. They found no assoc w/ MUC5B promoter variant & SSc-ILD. (Suggesting ILD pathogenic mechanisms differ between RA and SSc) https://t.co/bBq52X0Mwq https://t.co/eu1IpaXGL8

Links:

Dr. John Cush RheumNow ( View Tweet)
MUC5 mutations not in SSc-ILD. Study of 2363 SSc-ILD, 3526 SSc w/o ILD & 15076 controls. They found no assoc w/ MUC5B promoter variant & SSc-ILD. (Suggesting ILD pathogenic mechanisms differ between RA and SSc) https://t.co/bBq52X0Mwq https://t.co/QdUzra1fnj

Links:

Dr. John Cush RheumNow ( View Tweet)
Cardiovascular Sequelae in Adults After Kawasaki Disease A long-term cohort study of children diagnosed with Kawasaki disease (KD) shows evidence of future adult cardiovascular complications and hospitalizations. These severe cardiovascular events clustered during the young KD https://t.co/zbo64gAV1H
Dr. John Cush RheumNow ( View Tweet)
Study of 90 Still's Dz pts w/ lung disease from AIDA network - mean age 36 yr; 36% male (13% from pediatrics). Lung findings: pleuritis 72%, parenchymal 34%, ARDS 9.5% & pulm HTN 2.3%. Parenchymal involvement assoc w/ sore throat, pericarditis, higher systemic score, but not https://t.co/4YIx2BwADe
Dr. John Cush RheumNow ( View Tweet)
Single-center Retrospective study of 4,736 RA, propensity matched 509 w/ RA-ILD vs 509 without ILD. In multivariate analysis RF positivity was an independent risk factor for RA-ILD (adj OR = 1.5) w/ signif nonlinear relationship observed, risk threshold @60 IU/mL Paradoxical https://t.co/0XtWnIsbmK
Dr. John Cush RheumNow ( View Tweet)
TNF Inhibitors in Takayasu's Arteritis A large, retrospective, multicenter study demonstrated the efficacy of intravenous infliximab and subcutaneous adalimumab in patients with Takayasu arteritis. https://t.co/lJbvaYnylO https://t.co/uRBruhW2Fd

Links:

Dr. John Cush RheumNow ( View Tweet)
Detailed comprehensive overview of GLP-1RAs and SGLT2 inhibitors - their benefits w/ inflammatory conditions, & potential antiinflammatory effects. Bi-directional interplay between obesity, inflammation, and comorbid diseases https://t.co/oAQsuWVbZO https://t.co/SNqngATBtv

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×